4//SEC Filing
Karydas Daphne 4
Accession 0001933414-25-000150
CIK 0001933414other
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 7:01 PM ET
Size
10.4 KB
Accession
0001933414-25-000150
Insider Transaction Report
Form 4
Karydas Daphne
Director
Transactions
- Exercise/Conversion
Common Stock
2025-11-13$10.20/sh+15,000$153,000→ 15,000 total - Sale
Common Stock
2025-11-13$45.81/sh−10,115$463,351→ 4,885 total - Sale
Common Stock
2025-11-13$46.36/sh−4,885$226,446→ 0 total - Exercise/Conversion
Stock Option
2025-11-13−15,000→ 17,900 totalExercise: $10.20Exp: 2035-02-13→ Common Stock (15,000 underlying)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.19 to $46.18. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.19 to $46.70. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]The stock option vests in 12 monthly installments following the date of grant.
Documents
Issuer
Mineralys Therapeutics, Inc.
CIK 0001933414
Entity typeother
Related Parties
1- filerCIK 0001816952
Filing Metadata
- Form type
- 4
- Filed
- Nov 12, 7:00 PM ET
- Accepted
- Nov 13, 7:01 PM ET
- Size
- 10.4 KB